Belgian nationwide cohort study on OAC use in AF 2013-2019: 📌Prevalent OAC use: 29% ↗️, NOAC > VKA since 2015 📌Incident OAC use: stable, NOAC > VKA before 2013 📌Treatment gap: female AF patients <75 years old followed in primary care FT: doi.org/10.1111/bcp.15…

Nationwide study with 254,478 AF patients: 1. NOACs vs VKAs: superior effectiveness, non-inferior to superior safety 2. NOACs vs NOACs: -> Comparable effectiveness -> Differential safety: lower major bleeding risk with api/dabi vs riva & api vs dabi/edo doi.org/10.3389/fphar.…

New Research: Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study frontiersin.org/articles/10.33… #pharmacology

Belangrijk bevolkingsonderzoek GLORIA GEZONDHEIDSMONITOR gesteund door multi-disciplinair team vanuit UGent UZ Gent imec in Vlaanderen & Stad Gent gaat komende 20 jaar 20.000 Gentenaars onderzoeken om impact veroudering te meten vrtnws.be/p.RajL6Wd8d

Nationwide study with 237,012 Afib patients: 📌 NOACs: 9%↘️ risk of dementia vs VKAs 🧠✅ -> ↘️ risk of vascular & other/unspecified dementia ✅ <-> similar risk of Alzheimer’s disease ❌ 📌 ↘️ risk with apixaban & edoxaban (not dabi/riva) FT: doi.org/10.1093/ageing…

Impact of frailty on the effectiveness & safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a nationwide cohort study #AFib #NOAC #frailty #EHJQCCO academic.oup.com/ehjqcco/advanc…

Three out of ten #AFib patients are frail, and have a higher mortality risk. What to expect from #NOACs in this setting? More on this >250k patients cohort study in academic.oup.com/ehjqcco/advanc… #EHJQCCO #cardiotwitter Prof Chris P Gale Diogo Santos Ferreira

Nationwide study with 254,478 Afib patients: -> Previous falls were independent predictors of intracranial bleeding and death -> NOACs had better benefit-risk profiles than VKAs in patients with a fall history, especially apixaban FT: authors.elsevier.com/sd/article/S23…

Nationwide study with 254,478 Afib patients: -> Polypharmacy (66% of patients): independent risk factor for thromboembolism, major bleeding and all-cause mortality -> NOACs: better benefit-risk profiles than VKAs if polypharmacy, especially apixaban FT: thieme-connect.de/products/ejour…

25 years of #AFib and #Stroke prevention at #Europace: you must read this one! Check it out ⬇️ academic.oup.com/europace/artic… Liverpool Centre for Cardiovascular Science Marco Proietti MD PhD Boriani Giuseppe Europace Editor-in-Chief

Proud and grateful to Prof. Lies Lahousse for having invited me to be part, as foreign expert, of the PhD Committee of Dr. Maxim Grymonprez at UZ Gent. A strong dissertation and a fantastic start to an hopefully fruitful collaboration! Università degli Studi di Milano @icsmaugeri

After 4 years of research on oral anticoagulants in patients with atrial fibrillation, I have finally obtained my PhD! Special thanks to my supervisor Lies Lahousse, the PhD evaluation committee Sofiegevaert Marco Proietti MD PhD @MirkoPe41401841 , and FWO

Nationwide study with 92,111 NOAC-treated Afib patients: -> NOAC adherence <90%: ↗higher risk of stroke/SE -> NOAC adherence <95%: ↗higher risk of bleeding and death -> Similar with OD & BID dosed NOACs FT: link.springer.com/article/10.100… Lies Lahousse

Impact of P-gp and CYP3A4-interacting drugs on clinical outcomes in patients with #AFib using #NOACs: a nationwide cohort study bit.ly/46ppwF6 Stefan Agewall Felice Gragnano Maxim Grymonprez Lies Lahousse #EHJPharmacotherapy #ESCYoung

Nationwide study with 193 072 #Afib patients using #NOACs: -> P-gp/CYP3A4 inhibitor use: 24% & 7% ↗higher risk of bleeding and death, resp -> P-gp/CYP3A4 inducer use: 31% ↗higher risk of stroke FT: bit.ly/46ppwF6 Lies Lahousse European Society of Cardiology Journals

Nationwide study, 193 072 #Afib patients using #NOACs: ->Pharmacodynamic drug interaction: 19% ↗ bleeding risk: P2Y12 inhib: +62% Corticosteroid: +53% SSRI/SNRI: +26% Aspirin: +14% NSAID: +10% ->↗️ICH risk: SSRI/SNRI (+50%) & corticosteroid (+49%) FT: rdcu.be/dqrET

#NOACs in #AFib 🫀 pts with #Polypharmacy 💊💉: 👀Read Editorial from Marco Proietti MD PhD mark romiti and Bernadette Corica Giulio Francesco Romiti original paper from Maxim Grymonprez and team🔗 thieme-connect.de/products/ejour… thieme-connect.de/products/ejour… #anticoagulation

💊 What is the impact of #polypharmacy on efficacy and safety of #DOAC in #AF? ⤵️ 🫀 >250.000 #AFib pts., 66% with polypharmacy 📈 Polypharmacy➡️increased #thromboembolism, #bleeding and death 👉 thieme-connect.de/products/ejour… Maxim Grymonprez Lies Lahousse #Cardiology #anticoag

🎉 Our manuscript is accepted in Thrombosis Research! Conducted in 201 Belgian pharmacies, we highlight the crucial role of skilled DDI management for safe DOAC use. 🌟 FT: authors.elsevier.com/a/1j3rKBEfCv5H9

Anticoagulant-related bleeding as a sign of underlying tumoral lesions in patients with #AF. An useful reminder. academic.oup.com/ehjopen/advanc…